UNSPSC 51111907: Sodium phenylbutyrate

This classification denotes a phenylbutyrate and antineoplastic agent with the molecular formula C10H11O2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NT6K61736T, chemically known as benzenebutanoic acid, sodium salt but generally known as sodium phenylbutyrate, which bears US NIH Compound Identifier 15585. European Medicines Agency schedules Sodium phenylbutyrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12586MIG.

World Health Organization schedules sodium phenylbutyrate in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SODIUM PHENYLBUTYRATE remains the US FDA Preferred Term for this commodity. Sodium phenylbutyrate bears US NLM identifiers UMLS ID C0718066 and NCI Concept Code C1440. SMILES: C1=CC=C(C=C1)CCCC(=O)[O-].[NA+].

UNSPSC 51111907 Sodium phenylbutyrate is a Commodity code covering a specialized pharmaceutical active ingredient used in treatment formulations for inherited metabolic and urea cycle disorders. State and local governments procure this product primarily through pharmacy benefit management programs, hospital systems, and specialized medical facilities that serve patients requiring long-term metabolic disease management. The code encompasses the bulk chemical compound itself, typically sourced through licensed pharmaceutical distributors and used in compounded or commercial drug formulations within hospital pharmacies, outpatient treatment centers, and state Medicaid programs. Issuing bodies include state health departments, county hospital systems, state university health centers, and municipal medical facilities that maintain specialized pharmacy operations for rare and orphan drug therapies.

The most recent state and local contract opportunities block contains no recorded solicitations under this code. Activity under UNSPSC 51111907 appears concentrated in routine pharmacy procurement channels — standing orders through established pharmaceutical wholesalers, GPOs, and state Medicaid purchasing agreements — rather than competitive RFP or IFB cycles. State health departments managing Medicaid drug formularies and large integrated health systems with metabolic disorder clinics remain the primary buyers, but these purchases typically occur through existing group purchasing contracts or framework agreements rather than open market solicitations. Geographic concentration follows population centers with tertiary care networks and specialized metabolic disease programs, though the source provides no specific recent jurisdictional activity detail.